文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

COVID-19后国家层面免疫恢复与DTP1无剂次负担:WUENIC 2010-2024描述性生态分析

Country-level immunization recovery and DTP1 no-dose proxy burden after COVID-19: a descriptive ecological analysis of WUENIC, 2010-2024.
PubMed 文献 · Vaccine · 2026-07-28

该研究基于WHO/UNICEF WUENIC 2010-2024年194个国家/报告实体的数据,评估COVID-19后免疫恢复及DTP1无剂次负担。2024年加权覆盖率DTP1为88.94%、DTP3为84.56%、MCV1为84.03%;未加权国家固定效应显示2024年较2019年DTP1下降1.80个百分点(95%CI -2.75至-0.84)。

要点

  • 2024年加权覆盖率DTP1 88.94%、DTP3 84.56%、MCV1 84.03%。
  • 未加权国家固定效应2024 vs 2019:DTP1降1.80个百分点,DTP3降2.09,MCV1降1.65。

核心结论

  • 全球加权覆盖率接近2019年水平,但实体层面在获取、系列完成、麻疹覆盖、恢复及数据审核方面存在信号。
  • 程序管理者应联合审视这些信号而非单一排名;分类为描述性且特定于数据修订版,非经验证的风险评分。

研究设计与样本

  • 描述性生态分析,使用2024年精确修订版WHO/UNICEF WUENIC记录,覆盖194个国家/报告实体2010-2024年数据。
  • 估计2019年以来恢复程度和DTP1无剂次代理负担,量化DTP3-MCV1重叠,并分配有序表型。
  • 进行源状态、目标人口加权、阈值及2025年精确修订版敏感性分析。

主要发现

  • 复现的2024年加权估计:DTP1 88.94%,DTP3 84.56%,MCV1 84.03%。
  • 未加权国家固定效应2024 vs 2019:DTP1 -1.80个百分点(95%CI -2.75至-0.84),DTP3 -2.09(-3.25至-0.93),MCV1 -1.65(-2.72至-0.58);目标人口加权估计更接近零且不精确。
  • 阈值变化最多重新分配13.4%的实体;使用2025年精确修订版记录且终点固定为2024年时,聚合指标相似,但194个共同实体中20个恢复类别和19个表型分配发生变化。

临床怎么用

  • 程序管理者应联合审视实体层面的获取、完成、麻疹覆盖、恢复和数据审核信号,而非依赖单一排名。

局限性

  • 分类为描述性且特定于数据修订版,非经验证的风险评分。
  • 目标人口加权估计更接近零且不精确。
  • 使用2025年精确修订版记录时,部分恢复类别和表型分配发生变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Global immunization averages can obscure entity-level shortfalls in access, series completion, measles coverage, and recovery from 2019. We assessed these signals. METHODS: The primary analysis used exact-2024-revision WHO/UNICEF WUENIC records for 194 countries/reporting entities during 2010-2024. We estimated recovery from 2019 and DTP1 no-dose proxy burden, quantified DTP3-MCV1 overlap, and assigned ordered phenotypes. We reproduced benchmarks and conducted source-status, target-population-weighted, threshold, and exact-2025-revision sensitivity analyses. RESULTS: Reproduced weighted 2024 estimates were 88.94% for DTP1, 84.56% for DTP3, and 84.03% for MCV1. Unweighted country fixed-effects estimates for 2024 versus 2019 were - 1.80 percentage points (95% CI -2.75 to -0.84) for DTP1, -2.09 (-3.25 to -0.93) for DTP3, and - 1.65 (-2.72 to -0.58) for MCV1; target-population-weighted estimates were closer to zero and imprecise. The DTP1 no-dose proxy count was 14.26 million; the top 20 entities accounted for 74.6%. Forty-five entities with DTP3 below 80% and MCV1 below 90% accounted for 72.8% of the proxy count. Threshold changes reassigned at most 13.4% of entities. With exact-2025-revision records and the endpoint fixed at 2024, aggregate metrics were similar, but 20 recovery-class and 19 phenotype assignments changed among 194 common entities. CONCLUSION: Aggregate coverage near 2019 levels coexisted with entity-level access, completion, measles, recovery, and data-review signals. Program managers should review them jointly, not as one ranking; assignments are descriptive and revision-specific, not validated risk scores.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li J, Wang Z, Gong Y, et al. Country-level immunization recovery and DTP1 no-dose proxy burden after COVID-19: a descriptive ecological analysis of WUENIC, 2010-2024. Vaccine. 2026. PMID: 42520643. doi:10.1016/j.vaccine.2026.128973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。